Sestan Mario, Kifer Nastasia, Sozeri Betul, Demir Ferhat, Ulu Kadir, Silva Clovis A, Campos Reinan T, Batu Ezgi Deniz, Koker Oya, Sapina Matej, Srsen Sasa, Held Martina, Gagro Alenka, Fonseca Adriana Rodrigues, Rodrigues Marta, Rigante Donato, Filocamo Giovanni, Baldo Francesco, Heshin-Bekenstein Merav, Giani Teresa, Kataja Janne, Frkovic Marijan, Ruperto Nicolino, Ozen Seza, Jelusic Marija
Department of Paediatrics, University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia.
University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey.
Semin Arthritis Rheum. 2023 Aug;61:152209. doi: 10.1016/j.semarthrit.2023.152209. Epub 2023 Apr 26.
IgA vasculitis (IgAV) (formerly Henoch-Schönlein Purpura, HSP) rarely causes severe skin lesions in children. The purpose of the research was to determine whether severe skin manifestations were associated with a more severe disease course.
Severe cutaneous manifestations were defined as presence of hemorrhagic vesicles, bullae, ulcerations and/or necroses. Data were collected retrospectively from 12 international tertiary university medical centers.
A total of 64 patients with the most severe skin changes in IgAV/HSP and median (Q, Q) age of 8.08 (5.08, 11.92) years at the disease onset were compared with 596 IgAV/HSP patients without these manfiestations and median (Q, Q) age of 6.33 (4.50, 8.92) years. The patients with severe cutaneous manifestations were older in comparison to other patients with IgAV/HSP (p<0.001), they developed nephritis more frequently (40.6% vs. 20.6%, p = 0.001) with worse outcome of renal disease (p = 0.001). This group of patients also had higher frequencies of severe gastrointestinal complications like hematochezia, massive bleeding and/or intussusception (29.3% vs. 14.8%, p<0.001). d-dimer concentrations were significantly higher in these patients (4.60 mg/L vs. 2.72 mg/L, p = 0.003) and they had more frequent need for treatment with systemic glucocorticoids (84.4% vs. 37.2%, p<0.001) in comparison with the control group. Further multivariate analysis showed that severe cutaneous changes were associated with higher risk of developing nephritis [OR=3.1 (95%CI 1.04-9.21), p = 0.042] and severe gastrointestinal complications [OR=3.65 (95%CI 1.08-12.37), p = 0.038].
Patients with IgAV/HSP and severe skin manifestations had a more severe clinical course and more frequently required glucocorticoids compared to classic IgAV/HSP patients.
IgA 血管炎(IgAV)(原称过敏性紫癜,HSP)在儿童中很少引起严重皮肤病变。本研究的目的是确定严重皮肤表现是否与更严重的病程相关。
严重皮肤表现定义为存在出血性水疱、大疱、溃疡和/或坏死。数据从 12 家国际三级大学医学中心回顾性收集。
共比较了 64 例 IgAV/HSP 中皮肤变化最严重的患者,发病时中位(四分位间距)年龄为 8.08(5.08,11.92)岁,与 596 例无这些表现的 IgAV/HSP 患者,中位(四分位间距)年龄为 6.33(4.50,8.92)岁。与其他 IgAV/HSP 患者相比,有严重皮肤表现的患者年龄更大(p<0.001),他们更频繁地发生肾炎(40.6% 对 20.6%,p = 0.001),肾病结局更差(p = 0.001)。这组患者严重胃肠道并发症如便血、大量出血和/或肠套叠的发生率也更高(29.3% 对 14.8%,p<0.001)。这些患者的 D-二聚体浓度显著更高(4.60mg/L 对 2.72mg/L,p = 0.003),与对照组相比,他们更频繁地需要全身糖皮质激素治疗(84.4% 对 37.2%,p<0.001)。进一步的多因素分析表明,严重皮肤变化与发生肾炎的较高风险相关[比值比(OR)=3.1(95%置信区间 1.04 - 9.21),p = 0.042]和严重胃肠道并发症相关[OR = 3.65(95%置信区间 1.08 - 12.37),p = 0.038]。
与典型的 IgAV/HSP 患者相比,有严重皮肤表现的 IgAV/HSP 患者临床病程更严重,更频繁地需要糖皮质激素治疗。